Negative in Ames, in vitro chromosome aberration and rat bone marrow micronucleus assays
“BHV-3000 was negative in Ames, chromosomal aberration, and rat bone marrow micronucleus assays.”
✓ VerifiedFDA pharmacology/toxicology review, p. 58Source ↗
Carcinogenicity
26-week Tg.rasH2 mouse and 2-year rat: no drug-induced tumors
“Based on a review by the CDER Division of Biometrics, BHV-3000 did not induce tumor formation in the 26-week and 2-year carcinogenicity studies in TgRasH2 mice (0, 30, 100 300 mg/kg) and SD rats (0, 5, 15, 45 mg/kg), respectively.”
✓ VerifiedFDA pharmacology/toxicology review, p. 58Source ↗
Instead of carcinogenicity
Not stated in public reviews
Not reported in the public reviews. Reviewers summarise selectively, so this usually means it wasn't discussed publicly, not that it wasn't studied.
Instead of genotoxicity
Not stated in public reviews
Not reported in the public reviews. Reviewers summarise selectively, so this usually means it wasn't discussed publicly, not that it wasn't studied.
DRG histopathology
Not stated in public reviews
Not reported in the public reviews. Reviewers summarise selectively, so this usually means it wasn't discussed publicly, not that it wasn't studied.
Reproductive & developmental
Rat fertility: uterine atrophy >25 mg/kg, reduced conception at 150 mg/kg; no embryofetal toxicity in rat or rabbit
“Two fertility studies in SD rat indicated uterine atrophy at doses greater than 25 mg/kg, and decreased conception and increased pre-implantation loss at 150 mg/kg. There was no embryofetal toxicity in rat or rabbit.”
✓ VerifiedFDA pharmacology/toxicology review, p. 9Source ↗
Safety pharmacology
No CNS, cardiovascular or respiratory effects; hERG and sodium channel IC50 >30 µM
“There were no effects of BHV-3000 on CNS, cardiovascular, or respiratory safety pharmacology endpoints, and the IC50 for hERG or sodium ion channels was estimated to be in excess of 30 uM.”
✓ VerifiedFDA pharmacology/toxicology review, p. 9Source ↗
Genotox: Ames
Negative
“Rimegepant was negative in a standard battery of genetic toxicology (Ames, in vitro chromosomal aberration in Chinese hamster ovary cells, in vivo male Sprague-Dawley rat micronucleus) assays.”
✓ VerifiedFDA pharmacology/toxicology review, p. 4Source ↗
Genotox: in vitro mammalian
Chromosomal aberration in CHO cells: negative
“Rimegepant was negative in a standard battery of genetic toxicology (Ames, in vitro chromosomal aberration in Chinese hamster ovary cells, in vivo male Sprague-Dawley rat micronucleus) assays.”
✓ VerifiedFDA pharmacology/toxicology review, p. 4Source ↗
Genotox: in vivo
Rat micronucleus: negative
“Rimegepant was negative in a standard battery of genetic toxicology (Ames, in vitro chromosomal aberration in Chinese hamster ovary cells, in vivo male Sprague-Dawley rat micronucleus) assays.”
✓ VerifiedFDA pharmacology/toxicology review, p. 4Source ↗
Carcinogenicity model
Short-term Tg.rasH2 mouse and 2-year SD rat: not carcinogenic
“Rimegepant was not carcinogenic in a short-term study in hemizygous Tg.rasH2 mice and a 2 year lifespan study in Crl:CD(SD) rats.”
26-week Tg rasH2 mouse and 2-year rat completed before the marketing application
“Based on a review by the CDER Division of Biometrics, BHV-3000 did not induce tumor formation in the 26-week and 2-year carcinogenicity studies”
✓ VerifiedFDA pharmacology/toxicology review, p. 58Source ↗
hERG / QT
hERG and sodium channel IC50 >30 µM; no cardiovascular safety pharmacology effects
“There were no effects of BHV-3000 on CNS, cardiovascular, or respiratory safety pharmacology endpoints, and the IC50 for hERG or sodium ion channels was estimated to be in excess of 30 uM.”
✓ VerifiedFDA pharmacology/toxicology review, p. 9Source ↗
Not genotoxic overall: Ames negative; in vitro chromosome aberration positive without (not with) metabolic activation; rat micronucleus and comet negative